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The incidental finding of an isolated
splenomegaly during clinical assessment
of patients evaluated for unrelated causes
has become increasingly frequent be-
cause of the widespread use of imaging.
Therefore, the challenging approach to
the differential diagnosis of spleen disor-
ders has emerged as a rather common
issue of clinical practice. A true diagnos-
tic dilemma hides in distinguishing patho-
logic conditions primarily involving the
spleen from those in which splenomegaly
presents as an epiphenomenon of hepatic
or systemic diseases. Among the causes
of isolated splenomegaly, lymphoid malig-
nancies account for a relevant, yet prob-
ably underestimated, number of cases.
Splenic lymphomas constitute a wide and
heterogeneous array of diseases, whose
clinical behavior spans from indolent to
highly aggressive. Such a clinical hetero-
geneity is paralleled by the high degree of
biologic variation in the lymphoid popula-
tions from which they originate. Neverthe-
less, the presenting clinical, laboratory,
and pathologic features of these diseases
often display significant overlaps. In this
manuscript, we present our approach to
the diagnosis and treatment of these rare
lymphomas, whose complexity has been
so far determined by the lack of prospec-
tively validated prognostic systems, treat-
ment strategies, and response criteria.
(Blood. 2011;117(9):2585-2595)
Introduction
Splenomegaly is a frequent yet challenging sign clinicians have to
deal with in daily clinical practice. A true diagnostic dilemma hides
in distinguishing pathologic conditions primarily involving the
spleen from those in which splenomegaly presents itself as an
epiphenomenon of hepatic or systemic diseases. Moreover, be-
cause of the widespread use of ultrasonographic imaging, physi-
cians often have to face such a diagnostic challenge in the setting of
patients in whom the incidental finding of a slight isolated
splenomegaly may be the only sign of an underlying disease.
Among the causes of isolated splenomegaly, malignant lympho-
mas account for a relevant, yet probably underestimated, number of
cases. As a secondary lymphoid organ, the spleen may be involved
by lymphoid neoplasms during their dissemination process. How-
ever, it rarely represents the exclusive site of the lymphomatous
burden. Basing on a mere anatomic criterion, the designation
“splenic lymphomas” (SLs) has been classically restricted to
neoplasms fulfilling this latter condition.1 Herein, we adopt a less
restrictive definition of SLs encompassing cases presenting with
splenic involvement and in which the disease may also extend to
the bone marrow (BM), peripheral blood (PB), and/or the liver, in
the absence of prominent lymph node involvement.2,3
In the present era of detailed biologic characterization of
lymphoid populations, the aforementioned categorization of SLs
may sound leaky. Indeed, SLs are composed of a wide and
heterogeneous array of diseases, whose clinical behavior spans
from indolent to highly aggressive (Table 1). The clinical heteroge-
neity of these lymphomas is paralleled by the high degree of
biologic variation in the lymphoid populations from which they
originate.4 Nevertheless, the presenting clinical, laboratory, and
pathologic features of such lymphoid malignancies display signifi-
cant overlaps, which justify grouping diverse entities under the
same “operative heading” of SLs.
In this manuscript, we present our diagnostic and therapeutic
approach to these rare malignancies (accounting for  6% of all
lymphoid neoplasms), whose complexity has been so far deter-
mined by the lack of prospectively validated prognostic systems,
treatment strategies, and response criteria.
Diagnostic workup
The clinical presentation of patients with SLs is varied, composing
truly asymptomatic patients with isolated splenomegaly, patients in
whom splenomegaly is associated with PB count changes, and
patients reporting constitutional symptoms and/or abdominal dis-
comfort secondary to massive spleen enlargement. Such nonspe-
cific pictures often cause patients to undergo extensive investiga-
tion for infective, hepatic, or hemolytic diseases by physicians of
diverse subspecialties before a lymphoid malignancy is suspected
(Table 2).5 In the subset of patients in which splenomegaly re-
mains “unexplained,” lymphomas account for the leading cause
(Table 3).6-8
When approaching patients with suspect SLs, our primary effort
is to achieve a diagnosis by integrating presenting clinical and
laboratory data with imaging, PB, and BM assessment, thus trying
to avoid splenectomy for diagnostic purposes. The main steps of our
diagnostic workup of SLs are schematically represented in Figure 1.
Clinical evidence
We always collect a detailed medical history, which is mainly
aimed to highlight the presence of specific clues that may be
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relevant for the diagnosis and/or management of SLs. These
include the presence of pathologic conditions, such as chronic
hepatitis C virus (HCV) and hepatitis B virus infection, autoim-
mune disorders (eg, systemic lupus erythematosus, autoimmune
thyroiditis), previous therapies with immunosuppressive agents or
tumor necrosis factor blockers, B-symptoms, and symptoms evoca-
tive of a rapid and/or massive spleen enlargement, such as left-flank
pain and feeling of abdominal fullness.
Some of this information may strengthen the suspicion of a
lymphoproliferative disorder, and some may be oriented toward a
specific diagnosis, such as anti-tumor necrosis factor treatment in
young patients with Crohn disease, raising the suspicion of hepato-
splenic T-cell lymphoma (HSTL), whereas some others might have
an impact on the further steps of the diagnostic workup, such as the
presence of HCV infection influencing the interpretation of the BM
histopathologic picture.9-12
A careful scrutiny of the patient’s past medical investigations
should always be performed. Specifically, any incidental finding of
slight cytopenia, which could have been overlooked or neglected
at routine checkup, should be noted and dated because it may
represent a precious insight into the presumptive onset and pace of
an underlying lymphoproliferation.
By physical examination, little can be inferred other than signs
related to spleen and/or liver enlargement because peripheral
lymph node involvement is only exceptionally observed in the
presentation of SLs.13-24 Nevertheless, we consistently complement
physical examination with the ultrasonographic assessment of
superficial lymphatic stations and abdomen to highlight any
lymphadenomegaly that could be eventually considered for subse-
quent histologic analysis.25
Similar to clinical presentations, baseline laboratory findings of
patients with SLs may be rather overlapping and thus poorly
informative for diagnostic purposes. Indeed, PB counts may be
normal or display slight to marked lymphocytosis with or without
cytopenia (mostly anemia and thrombocytopenia) of variable
degree, irrespective of the underlying lymphoma histotype.26
Together with 2-microglobulin and lactate dehydrogenase, well-
known surrogates of the neoplastic burden, the presence of HCV
infection, serum M component, and Coomb test should be consis-
tently checked because of their high prevalence in some SL
histotypes, such as splenic marginal zone lymphoma (SMZL).27,28
Diagnostic imaging
Most of the patients coming to our attention with a suspected SL
have already undergone imaging assessment as part of the diag-
nostic workup for their underlying unexplained splenomegaly.
Ultrasound (US) imaging of the abdomen and whole-body com-
puted tomography scan are mandatory in all patients and must be
performed on presentation when they are not already available.
B-mode US is adequate for determining the actual size of the
spleen.29 Moreover, it can provide key pieces of information
regarding the echo-texture of the splenic parenchyma, allowing
the detection of focal lesions with a high sensitivity.30 By contrast,
B-mode US displays poor sensitivity when a diffuse effacement of
the spleen occurs. As a result, the overall sensitivity of B-mode
US in the diagnosis of splenic lymphoma involvement is approxi-
mately 50%. Contrast-enhanced US does not add much to the
diagnostic potential of B-mode US when applied to the spleen31;
therefore, we do not perform it routinely as part of the SL
diagnostic workup.
As the “gold standard” investigation for clinical staging of
lymphomas, whole-body computed tomography scan allows deter-
mining whether the suspected lymphoproliferative disorder is
confined to the spleen or it involves other nodal and/or extranodal
Table 1. Lymphoid malignancies that may present as SLs
Lymphomas commonly/typically presenting as SLs*
SMZL
SL-u
Splenic diffuse red pulp B-cell lymphoma
HCL variant
HCL
LL
B-PLL
T-LGL
Hepatosplenic T-cell lymphoma
Primary splenic presentations* of nodal lymphomas
MCL
FL
DLBCL-not otherwise specified
Micronodular T-cell/histiocyte-rich large B-cell lymphoma
*Splenic presentation encompasses cases with splenic involvement and in which
the disease may extend also to the BM, PB, and/or the liver, in the absence of
prominent lymph node involvement.
Table 2. Overview of the pathologic conditions, other than
lymphomas, causing splenomegaly
Disease type Representative examples
Infective Brucellosis, EBV and CMV infections,
Leishmaniasis, viral hepatitis
Myeloproliferative neoplasms PMF, CML, PV, CMML
Hemolytic anemia Thalassemia, sickle cell anemia,
hereditary spherocytosis, autoimmune
hemolytic anemia
Hepatic diseases and veno-
occlusive disorders of hepatic
veins and portal system
Cirrhosis, hepatic/portal/splenic vein
thrombosis
Autoimmune and inflammatory
diseases
SLE, Felty syndrome, sarcoidosis,
inflammatory pseudotumor of the spleen
Tumors Littoral cell angioma, hemangioma,
lymphangioma, spindle-cell sarcomas,
metastases
Protein misfolding diseases and
thesaurismoses
Amyloidosis, Gaucher disease, Erdheim-
Chester disease
Other conditions Cysts, infarction
EBV indicates Epstein-Barr virus; CMV, cytomegalovirus; PMF, primary myelofi-
brosis; CML, chronic myelogenous leukemia; PV, polycythemia vera; CMML, chronic
myelomonocytic leukemia; and SLE, systemic lupus erythematosus.
Table 3. Incidence of different pathologic conditions underlying
unexplained splenomegaly, according to 3 recent diagnostic
splenectomy series
Disease type
Kraus et al6
(2001),
no. (%)
Carr et al7
(2002),
no. (%)
Pottakkat et al8
(2006),
no. (%)
Lymphoid malignancies 69/122 (57) 8/18 (44) 15/41 (36.5)
Infective 0 0 8 (19.5)
Myeloproliferative neoplasms 3 (2.5) 0 0
Hepatic diseases and veno-
occlusive disorders of hepatic
veins and portal system
2 (1.5) 6 (33) 16 (39)
Autoimmune and inflammatory
diseases
7 (6) 4 (23) 0
Tumors 26 (21) 0 2 (5)
Other conditions 15 (12) 0 0
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sites. Moreover, it represents an optimal complementary assess-
ment of the spleen architecture to B-mode US.32
To date, there is no indication for routine fluorodeoxyglucose
positron emission tomography scan in the diagnostic approach and
staging of SLs; likewise, there is no routine role for magnetic
resonance imaging.33,34 In our practice, fluorodeoxyglucose posi-
tron emission tomography is only performed as an integrative
pretreatment staging procedure in high-grade SLs.
PB evaluation
Most of the entities included among SLs almost invariably show
the presence of neoplastic cells in the PB. Such circulating
components may rarely configure an overt leukemic picture or,
more frequently, consist of a subtle spillover of splenic and marrow
infiltrates, such as in some cases of SMZL or hairy cell leukemia
(HCL).18,35,36 PB examination is therefore a mandatory step in the
diagnostic workup of SLs. We pay particular attention to data that
can be inferred by the morphologic evaluation of May-Grunwald-
Giemsa–stained PB smears. On the one hand, it may allow the
identification of peculiar cell types, such as hairy cells, prolympho-
cytes, villous lymphocytes, basophilic villous lymphocytes, large
and granular lymphocytes, and plasmacytoid lymphocytes, which
may trigger the suspicion of a specific lymphoproliferative disease
(Figure 2). On the other hand, it may highlight the presence of
atypical lymphoid populations, and this information may prove of
value for the subsequent flow cytometric, histopathologic, and
immunohistochemical analyses. Informative examples may be that
of HSTL, which may show circulating atypical cells that can be
overlooked on flow cytometry being commonly CD4 CD8 T-cell
receptor-, and that of rare leukemic variants of follicular
lymphomas displaying circulating “buttock” cells.12,37
By flow cytometry, the surface phenotype of the circulating
component of SLs can be determined, and a definite diagnosis can
Figure 1. Schematic representation of the main steps of the SL diagnostic workup.
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be performed in HCL, mantle cell lymphoma (MCL), and T-cell
large granular lymphocytic leukemia (T-LGL), when all the
expected immunophenotypic features of these neoplasms are
present (Table 4).26,38 PB flow cytometry may also prove conclu-
sive for the diagnosis of HSTL, provided that  and  T-cell
receptor expression is tested on the basis of a specific clinical
suspect.12 By contrast, in SMZL, splenic lymphoma/leukemia
unclassifiable (SL-u), and lymphoplasmacytic lymphoma (LPL), a
precise diagnosis may not be achieved by flow cytometry alone
because of the lack of specific phenotypic markers (Table 4).39 In
such cases, a generic diagnosis of B-cell chronic lymphoprolifera-
tive disorder can be confidently performed at this stage of the
diagnostic workup.
A challenging issue is represented by B-cell splenic lymphomas
in which CD5 is even partially expressed by the neoplastic clone as
part of an aberrant phenotype not fulfilling the criteria for chronic
lymphocytic leukemia and MCL diagnosis because the differential
diagnosis of these cases includes CD5 SMZL, SL-u cases, CD5
LPL cases, and atypical chronic lymphocytic leukemia and MCL
cases.36,38,40,41 In these cases, in situ hybridization for CCND1/
immunoglobulin H (IgH) gene fusion should be consistently tested,
and any attempt at subclassification should be deferred until
Figure 2. Morphologic clues of SL neoplastic cells
in the PB. May-Grunwald-Giemsa stain: original magni-
fication 630. Images were captured by a Leica DM
3000 optical microscope, Leica DFC 320 digital camera,
and Leica IM50 software.
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cytogenetic, biomolecular, and histopathologic data are available.
The finding of CD10 marker expression on a circulating light-chain
restricted mature B-cell population is suggestive of germinal
center-derived lymphomas but does not permit differentiation
between follicular (FL) and diffuse large B-cell lymphomas
(DLBCLs), whose definite diagnosis relies on histopathologic and
molecular clues.42 Finally, the existence of several diagnostic
pitfalls, such as MCL with partial or absent CD5 expression,
CD10- FL, and clonal B-cell populations lacking clear-cut light-
chain restriction, suggests a note of caution about relying exclu-
sively on flow cytometry for rendering a diagnosis.38,42
BM evaluation
In SLs, the BM is almost constantly involved, even when the
leukemic component is inconspicuous. Therefore, the BM repre-
sents the most easily accessible tissue for the histopathologic
analysis. At the same time, it is an invaluable source of fresh cells
for immunophenotypic, biomolecular, and cytogenetic characteriza-
tion of the neoplastic clone.43 On these premises, we recommend to
always perform both BM aspirate and trephine biopsy.
Some of the key features that can be determined on BM
evaluation are highlighted in Table 5.
On BM histopathologic and immunohistochemical examina-
tion, a conclusive diagnosis can be reached in several lymphoid
neoplasms presenting as SLs. These include HCL, T-LGL, and
B-prolymphocytic leukemia, in which the BM evaluation repre-
sents the diagnostic “gold standard” according to the 2008 World
Health Organization classification of tumors of hematopoietic
and lymphoid tissues.44-46 Moreover, BM assessment makes it
possible to reach an accurate diagnosis in most cases of MCL,
HSTL, LPL, and SMZL, even in the absence of lymph node or
spleen assessment.12,17,27,35
SLs of germinal center B-cell derivation may be difficult to
classify in the BM because of the lack of germinal center-
associated phenotypic and cytogenetic/molecular markers, which
has been reported in a considerable fraction of primary splenic FL
cases.22 In addition, diagnosis of micronodular T-cell/histiocyte-
rich large B-cell lymphoma in the BM may prove challenging,
given the puzzling effect of the rich and heterogeneous clone-
associated reactive environment.24
On BM colonization, most lymphomas/leukemias included in
the category of SLs display a marked tropism for the BM vascular
niche, which shares several features (eg, cellular composition and
adhesion profile) with the splenic red pulp and liver sinusoidal
vasculature.47 This is reflected by the tendency of neoplastic cells to
lodge inside the BM sinusoids giving rise to a peculiar intrasinusoi-
dal infiltration, which can be observed either alone or in combina-
tion with interstitial and/or nodular infiltrates (Figure 3A).48 Such
an intrasinusoidal BM infiltration has been regarded as a hint to
support the diagnosis of SMZL when in the context of an
appropriate clinical picture, PB morphology, and immunopheno-
type.49 A prominent, almost exclusive, intrasinusoidal infiltration
characterizes also the splenic diffuse red pulp small B-cell lym-
phoma and hairy cell leukemia-variant (Figure 3B), 2 largely
overlapping splenic neoplasms, whose distinction from SMZL is
mainly based on PB morphology and on immunophenotypic
features, such as prevalent IgG usage and high DBA-44 expres-
sion.50,51 Along with SMZL and SL-u, an intrasinusoidal compo-
nent is a common feature of T-LGL and HSTL BM infiltrates
(Figure 3C-D).45,52
A confounding element in the interpretation of BM assessment
of patients with suspected SL may be represented by the presence
of chronic HCV infection. Actually, in HCV-infected patients,
scattered reactive lymphoid aggregates are commonly detected in
the BM parenchyma.9 These lymphoid aggregates (usually account-
ing for up to 10% of the overall BM cellularity) display consider-
able overlap with neoplastic ones as far as morphology is con-
cerned, being predominantly sited in the intertrabecular areas of
the BM parenchyma and showing a nodular architecture with a
variable degree of interstitial and/or intrasinusoidal spread. On
immunohistochemistry, these aggregates display a mixed B and
T cellular composition, yet they may be indistinguishable from the
lymphomatous infiltrates of SLs lacking a diagnostic phenotypic
signature, such as SMZL, SL-u, and LPL. For these reasons, we
adopt particular caution in interpreting nonspecific BM lymphoid
infiltrates when in the context of HCV-infected patients with
suspect SL; and whenever possible, we repeat BM assessment after
6 months from the first biopsy in the attempt of highlighting
Table 4. SL entities
B-cell
Flow cytometry immunophenotype
 > 4 or < 0.5 sIg; cIg CD20 CD5 CD10 CD23 FMC7 CD11c CD25 CD103 CD38 Cyclin-D1
SMZL  ;/  /  /  / /  / 
SLL-u
SDRPBCL  /;  /      /  
HCL-v  ;         NA NA
HCL  ;         NA /
LPL  /;  / / /      
B-PLL    /  /     / 
MCL*  ;       /  / 
FL*  ;   / /     NA 
DLBCL* / /; /   /   NA  NA  
MTLBL* / /; /     NA NA NA NA  
T-cell TCR TCR CD2 CD3 CD5 CD7 CD4 CD8 CD25 CD16 CD56 CD57
T-LGL     / /      
HSTL        /   / 
	
 indicates 	-to-
 light chain ratio; sIg, surface immunoglobulin; cIg cytoplasmatic immunoglobulin; CD, cluster of differentiation; NA, not applicable; TCR, T-cell receptor;
SDRPBCL, splenic diffuse red pulp B-cell lymphoma; HCL-v, hairy cell leukemia variant; and MTLBL, micronodular T-cell rich histiocyte-rich diffuse large B-cell lymphoma.
 indicates usually positive (ie,  90% of cases or more are positive);, usually negative; and/ and/may be positive or negative (the first sign indicating the more
frequent condition).
*Primary splenic form.
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relevant changes in the extent, pattern, and composition of the BM
infiltrates that might suggest their neoplastic nature.
Splenectomy: the (in)dispensable
diagnostic procedure
As a result of the thorough application of the aforementioned
diagnostic workup integrating clinical and imaging data, and data
from PB and BM investigations, most cases of lymphomas
presenting as unexplained splenomegaly can be recognized as
specific B- or T-cell lymphoma histotypes. However, in a minority
of cases, the output of such a diagnostic workup can be that of a
generic diagnosis of B-cell chronic lymphoproliferative disorder,
or it can even leave the nature of the splenomegaly unsolved
(Figure 1). In these conditions, spleen histology represents the only
mean for reaching a conclusive diagnosis. However, even spleen
histology is not free of diagnostic pitfalls, which lie in the possible
occurrence of overlapping patterns of infiltration among different
lymphoma entities and in the expression of aberrant immunopheno-
types by neoplastic clones.53 Altogether, these pitfalls issue strong
warning about considering diagnostic splenectomy as an easy
shortcut to a prompt SL diagnosis. As in BM assessment, such
pitfalls may represent a challenge, even for experienced hemato-
pathologists, and can only be overcome through a consistent
integration of clinical, biomolecular, and cytogenetic data.
We always resort to diagnostic splenectomy when neither PB
examination nor BM assessment highlights the presence of a
lymphoid neoplastic clone, which in our experience occurs in
approximately 5% of SL cases. Similarly, we always perform
splenectomy for diagnostic purposes when BM assessment triggers
a differential diagnostic problem between splenic FL and large
B-cell lymphoma, which would affect treatment choices and
outcome expectations.54
By contrast, our approach to patients receiving a generic
diagnosis of B-cell chronic lymphoproliferative disorder after PB
and BM assessment is to avoid splenectomy as a mere diagnostic
refinement. Given the indolent pace of the SLs commonly falling in
this “basket diagnosis,” namely, SMZL, SL-u, and LPL, allowing
the adoption of a watchful waiting policy,36,55 we consider splenec-
tomy only when it fully matches the need of a therapeutic
intervention. However, even in this setting of patients, there are few
exceptions in which a further diagnostic characterization through
spleen histology is of strong clinical relevance. These include rare
cases in which the suspect of a mantle cell lymphoma persists
despite PB and BM investigations,40 and cases in which an
underlying high-grade lymphoma (or high-grade transformation)
is suspected on the basis of focal lesions on spleen imaging,
B-symptoms, or laboratory findings (eg, high lactate dehydroge-
nase levels).56
Elective open splenectomy has rather low, yet sizeable (particu-
larly among elderly patients), morbidity and mortality rates account-
ing for approximately 12% and less than 1%, respectively57; these
rates are even lower for laparoscopic splenectomy, which can also
be safely performed in cases of massive splenomegaly.58 In this
Table 5. Diagnostic key features that can be determined on BM evaluation in SLs
Disease
entity Neoplastic cell morphology Infiltration pattern Additional diagnostic clues
SMZL Small round lymphocytes and medium-sized cells with
dispersed chromatin and pale cytoplasm
Intrasinusoidal with or without
interstitial and nodular
component
del(7q) in up to 40% of cases; surface IgM and IgD
expression
SLL-u
SDRPBCL Small- to medium-sized lymphocytes similar to those of
SMZL
Intrasinusoidal Frequent IgG surface expression; strong DBA-44
positivity
HCL-v Medium-sized cells with oval or convoluted nuclei and
prominent central nucleoli resembling prolymphocytes
Intrasinusoidal Absence of significant reticulin fibrosis, annexin-A1
negative constant IgG surface expression
HCL Small- to medium-sized lymphocytes with oval or
indented nuclei, homogeneous chromatin and
abundant cytoplasm
Loose interstitial or patchy Specific annexin-A1 expression; increase in reticulin
fibers
LPL Small lymphocytes admixed with plasmacytoid
lymphocytes and plasma cells
Nodular; interstitial or diffuse Cytoplasmic Ig expression (mostly IgM); 6q- in up to 50%
of BM-based cases; abundant mast cell infiltration
B-PLL Medium-sized cell with round nucleus, moderately
condensed chromatin, and prominent nucleolus
Interstitial; nodular del(17p) in 50% of cases
MCL Small- to medium-sized lymphoid cells with slightly to
markedly irregular nuclei, dispersed chromatin, and
inconspicuous nucleoli; blastoid variant shows larger
cells resembling prolymphocytes
Dense interstitial; diffuse t(11;14)/CCND1 rearrangement
FL Small lymphocytes with slightly irregular nuclei and
abundant pale cytoplasm.
Paratrabecular; nodular t(14;18)/BCL2 rearrangement; BCL2 and BCL6 IHC
expression
DLBCL Neoplastic cells in the BM may be large or more
frequently medium-sized lymphocytes resembling
those of low-grade B cell lymphomas
Nodular; interstitial; diffuse IRF4/MUM-1 IHC expression in up 65% of cases
MTLBL Few scattered large B-cells intermingling with small T and
B lymphocytes, and macrophages
Nodular; paratrabecular
T-LGL Large and granular lymphocytes with moderate to
abundant cytoplasm and azurophilic ganules
Intrasinusoidal and interstitial IHC expression of TIA-1, granzyme-B, and granzyme-M
HSTCL Monotonous medium-sized cells with round nuclei and a
rim of pale cytoplasm or atypical large cells with blastic
morphology
Intrasinusoidal Hyperplasia of the noninvolved marrow with or without
dysplastic features; hemophagocytic histiocytosis
CCND1 indicates cyclin D1; IHC, immunohistochemistry; SDRPBCL, splenic diffuse red pulp B-cell lymphoma; HCL-v, hairy cell leukemia variant; and MTLBL,
micronodular T-cell rich histiocyte-rich diffuse large B-cell lymphoma.
2590 IANNITTO and TRIPODO BLOOD, 3 MARCH 2011  VOLUME 117, NUMBER 9
For personal use only.on November 14, 2016. by guest  www.bloodjournal.orgFrom 
latter procedure, implying the fragmentation of the splenic paren-
chyma, a higher degree of caution is required to avoid excessive
distortion of samples during removal, which may flaw histopatho-
logic assessment.
Alternate options to splenectomy for diagnostic purposes are
represented by echo-guided spleen biopsy and fine needle aspira-
tion which, especially in the setting of peripheral splenic focal
lesions, have purportedly been shown to have good diagnostic
accuracy and low morbidity.59 Anyway, we do not perform these
procedures as part of the routine diagnostic workup of SLs.
Treatment strategies in SLs
Despite a shared presentation and clinical findings showing consid-
erable overlap, SLs have little in common as far as the therapeutic
strategies are concerned. A first “gross” distinction can be operated
between rare splenic forms of lymphomas that usually arise in
lymph nodes, such as FL, MCL, and DLBCLs, and lymphomas/
leukemias in which the splenic presentation (and BM involvement)
is frequent or even typical (eg, SMZL, T-LGL; Table 1).
Lymphomas belonging to the first of the aforementioned
categories may either maintain a common biologic and clinical
behavior when presenting as SLs, which supports the adoption of
the same therapeutic strategies used in their nodal counterparts, or
may display a frankly different behavior justifying ad-hoc therapeu-
tic interventions. In the treatment of these latter splenic “variants,”
the main limit is represented by the lack of standard treatment
because most of the therapeutic approaches so far reported mainly
derive from small retrospective series or anecdotic reports.
From the 2 reports so far published in the literature gathering
cases of primary splenic FL, a rather heterogeneous picture has
emerged as far as the biology of this SL is concerned. Actually,
most of the cases of primary splenic FL reported by Mollejo et al
were characterized by BCL2 and/or CD10 negativity (8 of 9 cases
and 4 of 9 cases, respectively) and by the absence of BCL2
translocation (8 of 8 cases), as well as by a high proliferation index
(7 of 9 cases) and rate of transformation toward DLBCL (3 of
8 cases).22 Conversely, all the cases of splenic FL reported by
Howard et al displayed biologic features paralleling those of nodal
FL cases.60 All cases of primary splenic FL included in these
2 reports underwent diagnostic splenectomy, which was followed
by either watchful waiting or systemic therapy ranging from
anthracycline-based therapy to stem cell transplantation, with
rituximab being administered in only 3 patients as monotherapy. At
present, there is not enough evidence of a diverse biologic and
clinical behavior of primary splenic FLs to support the adoption of
treatment strategies diverging from those of nodal FLs. For this
reason, the association of rituximab and polychemotherapy, whether
or not preceded by splenectomy, can be considered as the most
appropriate treatment for this setting of patients.61
The issue of treating MCL has been thoroughly discussed in a
recent article of this “How I Treat” series.62 In the splenic forms of
MCL, the neoplastic clone commonly shows an overt leukemic
dissemination and BM involvement and harbors a mutated Ig
repertoire with a higher frequency than nodal MCLs do.63 Splenec-
tomy has demonstrated impressive and durable responses in splenic
MCLs, producing a significant reduction of the circulating leuke-
mic component along with an effective recovery from cytopenia.64
Whether this seemingly indolent clinical behavior observed after
Figure 3. BM intrasinusoidal infiltration pattern in different SL entities. (A) SMZL: mixed nodular and intrasinusoidal infiltration. (B) SDRPSBCL: neoplastic cells are
exclusively lodged inside the dilated sinusoids. (C) T-LGL: subtle intrasinusoidal and interstitial infiltration. (D) HSTL: highly atypical large neoplastic cells engulf the BM
sinusoids. (A-B) Anti-CD20 immunostaining using the streptavidin-biotin-peroxidase complex and 3–3-diaminobenzidine (brown signal). (C-D) Anti-CD3 immunostaining
using the streptavidin-biotin-peroxidase complex and 3–3-diaminobenzidine (brown signal). (A-D) Original magnification 200. Images were captured by a Leica DM 3000
optical microscope, Leica DFC 320 digital camera, and Leica IM50 software.
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splenectomy is expression of a peculiar biology of the neoplastic
clone or a consequence of the massive tumor debulking provided
by spleen removal is not clear. Even if endorsed with a high
therapeutic efficacy, splenectomy should be regarded as a palliative
treatment, whose main limit lies in the persistence of a BM
neoplastic cell reservoir. Therefore, our approach to splenic MCL
patients is that of performing splenectomy as first-line treatment
and then pursuing the attainment of a complete remission through
chemo-immunotherapy administration in all the eligible patients,
including those who experienced a complete hematologic response
to splenectomy. Specifically, we adopt rituximab  cyclophosph-
amide, vincristine, doxorubicin, prednisone (R-CHOP) q21 
3 alternating with rituximab  high-dose cytarabine 2 times.65
DLBCLs of the spleen behave as aggressive neoplasms as those
arising in lymph nodes and other extranodal sites do. Hence,
treatment of these SLs should be guided by the same general
recommendations proposed for DLBCLs.66 In the rare patients
presenting with DLBCL confined to the spleen, who are splenecto-
mized for diagnosis, we follow the same strategy that we adopt
for DLBCL patients with surgically resected localized extranodal
disease and that involves the use of CHOP plus rituximab for
4 cycles. In all other cases of splenic DLBCL in which BM
histology and/or imaging demonstrate disease spread outside the
spleen, we perform restaging after 4 cycles of R-CHOP, with the
intention to treat patients 2 cycles past complete remission
achievement. Different from splenic DLBCL/not otherwise speci-
fied, the splenic form of the micronodular T-cell/histiocyte-rich
DLBCL subtype presents with a micronodular infiltration of the
spleen and the disease almost invariably involves the BM or other
extranodal sites. Most of the cases so far reported in the literature
have shown a rather dismal prognosis, with few recent exceptions
of cases treated with R-CHOP therapy.67 So far, our limited
experience with splenic T-cell/histiocyte-rich DLBCL patients does
not allow for personal indications for the treatment of this rare
lymphoma subtype.
As far as malignancies commonly or typically presenting
themselves as SLs are concerned, the therapeutic approach to HCL
and LPL has been detailed in 2 recent articles from the “How I
Treat” collection and therefore will not be discussed herein.55,68
B-cell prolymphocytic leukemia (B-PLL) is an aggressive
lymphoid malignancy whose poor response to treatment is in line
with the frequent occurrence of p53 mutation in the neoplastic
clone. The response rates so far obtained with a broad range of
treatments, including alkylating agents, combination chemotherapy
(CHOP), and purine analogs (pentostatin, fludarabine, and cladrib-
ine), range from 30% to 60%, with very few complete responders
(CRs;  20%) and an overall median survival rarely exceeding
3 years.69 The experience with monoclonal antibody-based immu-
notherapy in B-PLL is confined to few cases treated with alemtu-
zumab or rituximab.70 The attainment of durable CRs in the few
reported cases of pretreated B-PLL patients undergoing rituximab
therapy, along with the high expression of the CD20 target antigen
on B-PLL cells, make the use of rituximab in combination with
chemotherapy a sound option.71 In our experience, the main hurdle
in treating B-PLL patients consists of the advanced age and low
performance status of these frail subjects. Some of these patients
can be effectively, though temporarily, palliated through splenec-
tomy or splenic irradiation, which can produce a control over the
disease inducing the recovery of peripheral cytopenia, improve-
ment of the performance status, and even a considerable reduction
of lymphocytosis.70 Taking into account the invariably fatal course
of this disease, the adoption of allogeneic stem cell transplantation
should be considered on diagnosis in the rare young patients.
HSTL is a very rare lymphoma mainly affecting young men in
their second or third decade of life, who are commonly heavily
symptomatic because of cytopenia and huge hepatosplenomegaly.
In this extremely aggressive lymphoma showing a dismal progno-
sis with a median overall survival less than 2 years and poor
response to standard chemotherapy, we warrant the use of high-
dose cytarabine plus platinum-containing induction chemotherapy
consolidated with stem cell transplantation.12 In patients who are
not eligible for a transplantation procedure, a transient control over
the neoplastic clone outgrowth may be achieved by anthracycline-
containing chemotherapy, purine analogs, and/or alemtuzumab
immunotherapy. Splenectomy has little, if any, role in HSTL
patients because its efficacy in ameliorating peripheral cytopenia
may be flawed by the rather frequent occurrence of hemophago-
cytic histiocytosis in the BM.
As most other lymphoproliferative disorders falling in the
“basket” category of SLs, T-LGL lacks a standardized treatment.
The commonly indolent nature of this lymphoproliferative disor-
der, which in some cases may even border on a benign expansion
of cytotoxic T cells, candidates most patients to a watchful wait-
ing policy.72 We base the decision of starting treatment on the
appearance of signs and/or symptoms related to cytopenia. The
first-line therapy encompasses weekly low-dose methotrexate,
daily low-dose cyclosporine, or cyclophosphamide.72,73 Responses
to these treatments may require up to 3 months before becoming
clinically appreciable, and preservation of a “responder” status
requires continued maintenance therapy. Although these treatments
seem to be equally effective in inducing complete or partial
responses in a considerable percentage of patients (50%–80%), our
preference is for low-dose methotrexate (5-10 mg/m2) as in our
experience this drug proved to be manageable and well tolerated.
Because these immunosuppressant-based treatments barely affect
the tumor burden despite PB count amelioration, other options such
as purine analogs might be envisaged, especially in younger
patients. Indeed, purine analogs have been reported to produce
clinical responses in 40% to 60% of patients, lasting several
months after treatment discontinuation.72
In our clinical practice, nearly 80% of patients presenting with a
suspect SL are diagnosed with SMZL or SL-u. These lymphoid
malignancies, mainly occurring in the elderly, commonly pursue a
truly indolent course with approximately 70% of patients alive at
10 years from the diagnosis and nearly 30% of patients eventually
dying of causes unrelated with the lymphoma.74 Approximately
one-third of patients can be conveniently managed with a watchful
waiting policy for several years. However, a sizeable subgroup of
patients may display a progressive disease with a less favorable
outcome (56% of patients alive at 5 years).27,36 At present, there is
no indication that early treatment is able to affect the natural course
of these diseases; thus, decision-making about treatment in the
clinical practice should be based on symptoms and clinical
features. Actually, one notable exception to this rule of thumb is
represented by the presence of HCV infection, which, already on
presentation, candidate patients to receive antiviral therapy with
pegylated interferon- and ribavirin. In HCV SMZL patients
achieving clearance of HCV RNA after antiviral treatment, the
sustained virologic response has been reported to be paralleled by
the clinical remission of the lymphoproliferative disease in 75% of
cases.75,76 So far, we have treated 5 HCV SMZL patients with
pegylated interferon and ribavirin observing no responses; nonethe-
less, we still consider such an antiviral therapy approach sound and
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the attainment of HCV clearance a major clinical goal to be pursued
early in all HCV-infected SMZL patients.
We allocate presenting patients in different risk categories
according to the Intergruppo Italiano Linfomi prognostic score
system (Table 6).74 We follow up low-risk patients every 4 months
for history, physical examination, laboratory tests, and blood
counts with the aim of assessing disease steadiness. Once a stable
clinical course has been verified, less frequent follow-up is
adopted. Specifically, patients in whom the prognostic score and
the spleen size remain unchanged are followed-up every 6 months
without treatment, whereas those showing a switch in the prognos-
tic score and/or an increase in spleen size of at least 20% are
followed-up every 2 months. Similarly, in asymptomatic patients
who score as intermediate or high risk on presentation, we adopt a
watchful waiting policy with a 2-month follow-up and with the
prospect of starting treatment on clinical symptoms appearance.
Any alteration to this “waiting move” tactic will depend on the
definite demonstration of an improved survival from early institu-
tion of treatment based on upfront prognostic stratification. Nota-
bly, the core part of the “waiting move” lies in open communication
with the patient aiming to render her/him fully aware about the
natural course of her/his disease and about the subtle, yet crucial,
demarcation existing between “waiting” and “not taking care.”
The key steps of our treatment approach for the management of
previously untreated SMZL/SL-u patients are sketched out in
Figure 4.
The clinical signs and symptoms that most frequently trigger
our decision to undertake treatment are the development of marked
anemia (Hb  10 g/dL), abdominal uneasiness and left flank pain
secondary to huge splenomegaly, and constitutional symptoms.
Thrombocytopenia is only rarely severe and commonly does not
imply an increased hemorrhagic risk36; therefore, we usually defer
treatment of SMZL/SL-u patients with isolated thrombocytopenia
until a drop in platelets to 80  109/L is observed.
Table 6. SMZL IIL prognostic score
Risk factors
Hb  12 g/dL
LDH level higher than normal
Albumin level  3.5 g/dL
Score classes
Low risk: no risk factors (83% 5-year OS*)
Intermediate risk: 1 risk factor (72% 5-year OS*)
High risk: 2 or more risk factors (56% 5-year OS*)
IIL indicates Intergruppo Italiano Linfomi; Hb, hemoglobin; LDH, lactate dehydro-
genase; and OS, overall survival.
*95% confidence interval.
Figure 4. The key steps of our treatment approach for the management of previously untreated SMZL/SL-u patients.
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Effective recovery from cytopenia- and splenomegaly-related
symptoms is promptly obtained through splenectomy, which, in
most patients, may assure a long window period free of symptoms.
During this period, the disease persists in the BM and PB and will
eventually progress in a median time of 4 to 5 years.77 On these
bases, such a palliative treatment is regarded as the first choice
therapy in SMZL/SL-u, when a treatment is needed. For patients
who progress after splenectomy, as well as for those who are unfit
for splenectomy or unwilling to undergo surgery, systemic treat-
ment may be appropriate. However, which patients would benefit
most of such systemic therapy, which one would be the most
effective drug combination, and when treatment should be started
during the natural course of the disease, all remain open and
debated issues.36 A good control over the disease, and even
complete responses, can be achieved in naive (ie, not splenecto-
mized) and relapsed patients through therapy with purine analogs
( 20% CR) and immunotherapy with rituximab either alone or
in combination with chemotherapy ( 40% and 60% CR, respec-
tively).78-81 In our opinion, the remarkable response rates and low
toxicity so far observed with rituximab make this therapeutic
option strong enough to challenge the primacy of splenectomy as
the first-line treatment of choice. In our practice, we use rituximab
as monotherapy (375 mg/m2 weekly 4 to 6 times) in the first-line
treatment of frail patients and of patients with concurrent autoim-
mune manifestations in light of its low toxicity profile, although we
generally resort to the combination of rituximab and purine analogs
(R-cladribine, R-fludarabine) or rituximab and cyclophosphamide,
vincristine, myocet, and prednisone (R-COMP) for fit patients with
disseminated disease to nodal and extranodal sites other than the
spleen, and for patients with constitutional symptoms and/or signs
of high-grade transformation.82
Recently, bendamustine has emerged as a highly versatile drug
characterized by a peculiar mechanism of action, mild (mainly
hematologic) toxicity, and a broad spectrum of activity encompass-
ing almost all the mature B-cell neoplasms, including marginal
zone lymphomas.83,84 In line with this evidence, we have started
offering the association of rituximab plus bendamustine as a
second-line therapy option in relapsed or progressed patients. All
the 6 SMZL patients we have so far treated with rituximab plus
bendamustine have responded to this therapy, 4 of 6 obtained a CR
and, notably, none of the patients achieving a CR was splenecto-
mized. Altogether, the promising responses and the low toxicity
profile observed make the association of rituximab and bendamus-
tine worth investigating in specifically designed prospective trials.
In conclusion, while detailing how we diagnose and treat
splenic lymphomas, we went through the numerous open issues
that still cast their shadows over this group of malignancies and
evoke Alexander Pope’s description of “strange phantoms” lurking
in the “gloomy cave of Spleen.”85 Together, all these issues
represent a strong appeal for future cooperative efforts aimed to
obtain a deeper understanding of the biology of these disorders and
to prospectively investigate the efficacy of treatments, allowing the
switch from an experience-based to an evidence-based approach.
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